Disconnect between signalling potency and \textit{in vivo} efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

Maria Lucey\textsuperscript{1}, Philip Pickford\textsuperscript{1}, Stavroula Bitsi\textsuperscript{2}, James Minnion\textsuperscript{1}, Jan Ungewiss\textsuperscript{3}, Katja Schoeneberg\textsuperscript{3}, Guy A. Rutter\textsuperscript{2}, Stephen R. Bloom\textsuperscript{1}, Alejandra Tomas\textsuperscript{2,4*}, Ben Jones\textsuperscript{1,*4}

\textbf{ABSTRACT}

\textbf{Objective:} The objective of this study was to determine how pharmacokinetically advantageous acylation impacts on glucagon-like peptide-1 receptor (GLP-1R) signal bias, trafficking, anti-hyperglycaemic efficacy, and appetite suppression.

\textbf{Methods:} In vitro signalling responses were measured using biochemical and biosensor assays. GLP-1R trafficking was determined by confocal microscopy and diffusion-enhanced resonance energy transfer. Pharmacokinetics, glucoregulatory effects, and appetite suppression were measured in acute, sub-chronic, and chronic settings in mice.

\textbf{Results:} A C-terminally acylated ligand, $[\text{D}^3,G^{40},K^{41},\text{C}16 \text{diacid}]\text{exendin-4}$, was identified that showed undetectable $\beta$-arrestin recruitment and GLP-1R internalisation. Depending on the cellular system used, this molecule was up to 1000-fold less potent than the comparator $[\text{D}^5,G^{40},K^{41},\text{C}16 \text{diacid}]\text{exendin-4}$ for cyclic AMP signalling, yet was considerably more effective \textit{in vivo}, particularly for glucose regulation.

\textbf{Conclusions:} C-terminal acylation of biased GLP-1R agonists increases their degree of signal bias in favour of cAMP production and improves their therapeutic potential.

\textbf{Keywords} Type 2 diabetes; Biased signalling; Glucagon-like peptide-1 receptor; Exendin-4; Trafficking

1. \textbf{INTRODUCTION}

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective agents for the treatment of type 2 diabetes (T2D) and obesity\textsuperscript{[1]}. Their therapeutic effects derive mainly from potentiation of glucose-stimulated insulin secretion and suppression of appetite leading to weight loss, respectively mediated by GLP-1Rs expressed in pancreatic beta cells and anorectic neurons. GLP-1RAs are known to improve renal \textsuperscript{[2]} and cardiovascular outcomes \textsuperscript{[3]} in T2D and reduce mortality \textsuperscript{[4]}.

The predominant intracellular signalling intermediate that couples GLP-1R activation to its downstream effects is cyclic adenosine monophosphate (cAMP) \textsuperscript{[5,6]}. However, an updated view of GLP-1R signalling and trafficking, anti-hyperglycaemic effects, and appetite suppression were measured in acute, sub-chronic, and chronic settings in mice. Studies of orthosteric biased GLP-1R agonism have to date mainly used peptide ligands \textsuperscript{[11,12]}, sometimes featuring non-native amino acids such as the $\beta$-arrestins \textsuperscript{[9,10]} in the control of amplitude, duration, and subcellular localisation of signalling events to regulate insulin secretion, particularly in the pharmacological setting. Although all clinically approved GLP-1RAs show broadly similar signalling and trafficking characteristics to the endogenous ligand GLP-1(7–36)NH$_2$, these can be dramatically altered via sequence modifications close to the ligand N-terminus, as recently demonstrated using analogues of the GLP-1 homologue peptide exendin-4 \textsuperscript{[11,12]}. Specifically, “biased” GLP-1RAs that retain full efficacy for cAMP production but reduced $\beta$-arrestin recruitment and endocytic uptake are able to avoid GLP-1R desensitisation and downregulation that ordinarily attenuate glucoregulatory responses \textit{in vivo}. Additional effector proteins such as the $\beta$-arrestins \textsuperscript{[9,10]} in the control of amplitude, duration, and subcellular localisation of signalling events to regulate insulin secretion, particularly in the pharmacological setting. Although all clinically approved GLP-1RAs show broadly similar signalling and trafficking characteristics to the endogenous ligand GLP-1(7–36)NH$_2$, these can be dramatically altered via sequence modifications close to the ligand N-terminus, as recently demonstrated using analogues of the GLP-1 homologue peptide exendin-4 \textsuperscript{[11,12]}. Specifically, “biased” GLP-1RAs that retain full efficacy for cAMP production but reduced $\beta$-arrestin recruitment and endocytic uptake are able to avoid GLP-1R desensitisation and downregulation that ordinarily attenuate glucoregulatory responses \textit{in vivo}.

Studies of orthosteric biased GLP-1R agonism have to date mainly used peptide ligands \textsuperscript{[11,12]}, sometimes featuring non-native amino acids such as the $\beta$-arrestins \textsuperscript{[9,10]} in the control of amplitude, duration, and subcellular localisation of signalling events to regulate insulin secretion, particularly in the pharmacological setting. Although all clinically approved GLP-1RAs show broadly similar signalling and trafficking characteristics to the endogenous ligand GLP-1(7–36)NH$_2$, these can be dramatically altered via sequence modifications close to the ligand N-terminus, as recently demonstrated using analogues of the GLP-1 homologue peptide exendin-4 \textsuperscript{[11,12]}. Specifically, “biased” GLP-1RAs that retain full efficacy for cAMP production but reduced $\beta$-arrestin recruitment and endocytic uptake are able to avoid GLP-1R desensitisation and downregulation that ordinarily attenuate glucoregulatory responses \textit{in vivo}.

Studies of orthosteric biased GLP-1R agonism have to date mainly used peptide ligands \textsuperscript{[11,12]}, sometimes featuring non-native amino acids such as the $\beta$-arrestins \textsuperscript{[9,10]} in the control of amplitude, duration, and subcellular localisation of signalling events to regulate insulin secretion, particularly in the pharmacological setting. Although all clinically approved GLP-1RAs show broadly similar signalling and trafficking characteristics to the endogenous ligand GLP-1(7–36)NH$_2$, these can be dramatically altered via sequence modifications close to the ligand N-terminus, as recently demonstrated using analogues of the GLP-1 homologue peptide exendin-4 \textsuperscript{[11,12]}. Specifically, “biased” GLP-1RAs that retain full efficacy for cAMP production but reduced $\beta$-arrestin recruitment and endocytic uptake are able to avoid GLP-1R desensitisation and downregulation that ordinarily attenuate glucoregulatory responses \textit{in vivo}.
acid substituents [13–15]. While these ligands typically have been engineered for high proteolytic stability, rapid renal elimination [16] means that their half-lives are measured in hours, which is incompatible with a drive to reduce the frequency of injections for patient convenience, comfort, and adherence. The leading GLP-1RAs in current clinical usage have been chemically optimised to allow once-weekly dosing in humans through avoidance of renal clearance [1], for example through conjugation of a fatty acid chain to the peptide that promotes reversible binding to albumin and other plasma proteins that are too large to undergo glomerular filtration. However, these approved compounds show broadly comparable signalling characteristics, and biased GLP-1R agonism has not yet been studied using pharmacokinetically optimised agents.

In this study, we investigated the impact of acylating two oppositely biased GLP-1R agonists, exendin-phen1 (referred to in this manuscript as F¹-exendin-4) and exendin-asp3 (referred to as D³-exendin-4), both with identical amino acid sequences to exendin-4 except for at the first or third N-terminal amino acids, respectively [12]. We found that the introduction of a C-terminal fatty diacid chain to F¹-exendin-4 exaggerated the degree of bias at the expense of a reduced overall signalling potency. However, when tested in vivo, despite an up to ~1000-fold reduction in signalling potency, the acylated form of F¹-exendin-4 outperformed that of D³-exendin-4 for control of blood glucose over 72 h after a single dose, as well as providing greater glucose control and weight loss with repeated administration.

2. MATERIALS AND METHODS

2.1. Peptides

Peptides were produced by Wuxi AppTec Co., Ltd., using standard solid phase peptide synthesis. Mass spectrometric confirmation of peptide identity and high-performance liquid chromatographic purity assessment were provided by the manufacturer (all were of >90% purity).

2.2. Cell culture

HEK293 cells stably expressing human SNAP-GLP-1R (HEK293-SNAP-GLP-1R cells), HEK293T cells, PathHunter CHO—K1-Bant2-EA-GLP-1R cells (DiscoverX), INS-1 832/3 cells (a gift from Prof. Christopher Newgard, Duke University), and MIN6B1 cells (a gift from Prof. Philippe Halban, University of Geneva) were used in this study and maintained as previously described [12,17]. Full details are provided in the Supplementary Methods.

2.3. GLP-1R binding affinity measurement

Equilibrium binding assays were conducted using HEK293-SNAP-GLP-1R labelled with SNAP-Lumi4-Tb (Cisbio, 40 nM). Metabolic inhibitors (20 mMol/L 2-deoxyglucose and 10 mMol/L NaN₃) [18] were used to prevent GLP-1R internalisation during agonist binding. Cells were treated with exendin [9–39]-FITC in competition with a range of concentrations of unlabelled peptide for 24 h at 4 °C before measurement of binding by TR-FRET [17]. The baseline-subtracted TR-FRET ratio was used to quantify binding and equilibrium binding constants (Kᵦ) using Prism 8 (GraphPad Software). Full details are provided in the Supplementary Methods.

2.4. Cyclic AMP responses

Cells were stimulated with agonist for the indicated time period in their respective growth media. PBS was used when indicated. Assays were conducted at 37 °C without phosphodiesterase inhibitors except for INS-1 832/3 and MIN6B1 cells, where 3-isobutyl-1-methyloxanthine (IBMX) was added at 500 μM to detect ligand-induced responses in these less highly coupled cell models. At the end of the incubation period, the cells were lysed and cAMP was determined by homogeneous time-resolved fluorescence (HTRF, cAMP Dynamic 2 kit, Cisbio).

2.5. PathHunter β-arrestin recruitment assay

Cells were stimulated for 30 min in growth medium without FBS at 37 °C. The assay was terminated by the addition of PathHunter detection reagents and the luminescent signal was read from each well.

2.6. NanoBiT complementation assays

The plasmids for mini-G₁, -G₂, and -G₃, each carrying an N-terminal LgBiT tag [19], were a gift from Prof. Nevin Lambert, Medical College of Georgia. The plasmid for β-arrestin-2 fused at the N-terminus to LgBiT was obtained from Promega Custom Assay Services (plasmid CS16038118). The SmBiT was cloned in frame at the C-terminus of the GLP-1R by substitution of the Tango sequence on a FLAG-tagged GLP-1R-Tango expression vector [20], a gift from Dr. Bryan Roth, University of North Carolina (Addgene plasmid # 66295). HEK293T cells in 12-well plates were co-transfected for 24 h using Lipofectamine 2000 and the following quantities of DNA: 0.5 μg each of GLP-1R-SmBit and LgBiT-mini-G, or 0.05 μg each of GLP-1R-SmBit and LgBiT-mini-G with 0.9 μg empty vector DNA (pcDNA3.1). Cells were resuspended in Nano-Glo dilution buffer + fumarazyme (Promega) diluted 1:20 and seeded in 96-well half area white plates. Baseline luminescence was measured over 5 min using a Flexstation 3 microplate reader at 37 °C before the addition of ligand or vehicle. Responses were normalised to the average baseline.

2.7. PKA activation FRET assay

This assay was conducted as previously described [17]. Briefly, HEK293-SNAP-GLP-1R cells were transfected with PKA activation FRET biosensor AKAR4-NES (a gift from Dr. Jin Zhang, Addgene plasmid #61620) for 36 h, and FRET signal was recorded before and after ligand addition and expressed ratiometrically after normalisation to well baseline. Full details are provided in the Supplementary Methods.

2.8. Confocal microscopy

HEK293-SNAP-GLP-1R cells seeded on coverslips were labelled with SNAP-Surface 549 (New England Biolabs) prior to stimulation with the indicated agonist (100 nM) for 30 min, after which the cells were washed in PBS, fixed with 4% paraformaldehyde, mounted in Diamond Prolong mounting medium with DAPI, imaged with a Zeiss LSM780 inverted confocal microscope with a 63x/1.4 numerical aperture oil-immersion objective, and analysed in Fiji.

2.9. Animal studies

All of the animal procedures were approved by the British Home Office under the UK Animal (Scientific Procedures) Act 1986 (Project License PB70CFE7A). Animal husbandry details are provided in the Supplementary Methods.

2.10. Pharmacokinetic studies

Mice were injected intraperitoneally (ip) with 100 nmol/kg agonist and blood samples were obtained by venesection into lithium heparin-coated capillary tubes. Plasma exendin concentrations were measured using a fluorescent enzyme immunoassay (Phoenix Pharmaceuticals) that recognises the C-terminus of exendin-4 and has previously been used to measure the pharmacokinetics of N-terminally modified exendin-4 analogues [11,12]. As the manufacturer also

Brief Communication
reports full cross-reactivity with lixisenatide, a peptide with a similar amino acid sequence to exendin-4 except for a C-terminal modification featuring a hexalysine extension, we suspected it may also recognise the acylated peptides used in this study. At 0.1 nM, we found 50% cross-reactivity of acylated exendin-4 analogues compared to exendin-4 when spiked into mouse plasma, confirming a fully intact exendin-4 C-terminus is not mandatory for this assay. This correction factor was therefore applied to correct for reduced recovery of acylated peptides.

2.11. EScalate assay
The EScalate assay was conducted as previously described [21]. Full details are provided in the Supplementary Methods.

2.12. Glucose tolerance testing
Mice were fasted for 4–5 h before the test. Bodyweight-adjusted doses of glucose (2 g/kg) were IP injected with or without agonist prepared within the same injector as indicated. Blood samples were obtained immediately prior to injection and at 20-min intervals thereafter, and glucose was measured using a handheld glucose meter (Glucorex).

2.13. Food intake studies
For sub-chronic studies, mice were fasted overnight and diet was returned to the cage immediately after IP injection of agonist, with cumulative intake determined by weighing. For the chronic study, mice were fasted for 4–5 h during the light phase and diet was returned to the cage immediately after IP injection of agonist at the beginning of the dark phase.

2.14. Alpha and beta cell mass quantification
At the end of the agonist administration period, mice were sacrificed and the pancreata were dissected and fixed in 4% PFA for 24 h. Insulin- and glucagon-positive areas were quantified as previously described [22] and expressed relative to the total pancreas area imaged. Full details are provided in the Supplementary Methods.

2.15. Statistical analyses
Quantitative data were analysed using Prism 8.0 (GraphPad Software). In cell culture experiments, technical replicates were averaged so that each individual experiment was treated as one biological replicate. Dose responses were analysed using 4-parameter logistic fits, with constraints imposed as appropriate. Bias analyses were conducted as previously described [12,23]. Statistical comparisons were made by t-test or ANOVA as appropriate, with paired or matched designs used depending on the experimental design. Mean ± standard error of mean (SEM) or individual replicates are displayed throughout. Statistical significance was inferred if p < 0.05.

3. RESULTS

3.1. Impact of C-terminal acylation on in vitro pharmacology and trafficking of biased GLP-1Rs
The sequences of F1-exendin-4, D3-exendin-4, and their acylated equivalents [F1,G40,K41.C16 diacid]exendin-4 and [D3,G40,K41.C16 diacid]exendin-4 are shown in Figure 1A and Supplementary Figure 1A. The C16 hexadecanedioic acid moiety was inserted at the peptide C-terminus after a GK linker. This position was chosen to avoid the potential for fatty acids to interfere with putative interactions made by the peptide N-terminus with the GLP-1R, which are important for inducing signal bias. The equilibrium affinity of [D3,G40,K41.C16 diacid]exendin-4 was similar to that of D3-exendin-4 (Figure 1B, log Kd = 8.9 ± 0.1 vs 9.1 ± 0.1, respectively, p > 0.05 by one-way randomised block ANOVA with Sidak’s test), whereas [F1,G40,K41.C16 diacid]exendin-4 showed higher affinity for the receptor than its non-acylated counterpart (log Kd = 8.3 ± 0.0 vs 7.8 ± 0.0, respectively, p < 0.05 by one-way randomised block ANOVA with Sidak’s test).

Non-acylated F1-exendin-4 is known to display markedly reduced recruitment of β-arrestin-1 and -2, whereas non-acylated D3-exendin-4 is a full agonist in these pathways, both ligands being full agonists for cAMP [12]. To determine how acylation affects this established pattern of signal bias, we measured cAMP and β-arrestin-2 responses in PathHunter CHO–K1–βarr2-EA-GLP-1R cells. The expected signalling pattern was preserved (Figure 1C, Table 1), although both C16 ligands showed reduced efficacy for β-arrestin-2 recruitment compared to their non-acylated equivalents. Despite increased binding affinity, cAMP potency for [F1,G40,K41.C16 diacid]exendin-4 was reduced compared to that of F1-exendin-4. Due to the undetectable β-arrestin-2 response with [F1,G40,K41.C16 diacid]exendin-4, quantification of signal bias was not possible either using the most commonly used approach based on a modified form of the operational model of agonism [24,25], or an alternative method designed to aid bias quantification with extremely low efficacy agonists [23] (Supplementary Figure 1B).

Signalling potencies for cAMP at rat and mouse GLP-1Rs was also tested in INS-1 832/3 and MIN6B1 islet cells, respectively (Supplementary Figure 1C and D, Table 1). In these cells, which express the GLP-1R endogenously, the potency shift with [F1,G40,K41.C16 diacid]exendin-4 was more pronounced (up to 1000-fold reduction in MIN6B1 compared to [D3,G40,K41.C16 diacid]exendin-4), accompanied by reduced efficacy in INS-1 832/3 cells. These differences are more marked than for cells with GLP-1R exogenously expressed at high levels, for example, the experiments shown in Figure 1C. We also used NanoBiT complementation to monitor dynamic interactions of GLP-1R with β-arrestin-2 [26] and mini-Gαs, -Gβ, and -GαS protein probes [19] after stimulation with a maximal concentration of each ligand (Figure 1D; individual AUC quantifications are shown in Supplementary Figure 1D). Mini-Gαs and -Gβ recruitment responses were detectable in some cases but of low magnitude, confirming that Gαs is the preferred G protein coupled to GLP-1R activation. Both F1 ligands showed markedly reduced efficacy for Gαs recruitment compared to D3 ligands, and acylation was associated with a modest reduction in recruitment efficacy for each effector (see the heatmap in Figure 1D). Comparison of maximal responses in HEK293 cells for mini-Gαs recruitment, cAMP, and protein kinase A (PKA) activation highlighted how amplification within this pathway translates low efficacy G protein recruitment to high efficacy PKA signalling with F1 ligands in the context of virtually absent β-arrestin-2 recruitment (Supplementary Figure 1E).

Next, the four ligands were compared in HEK293-SNAP-GLP-1R cells for their propensity to induce GLP-1R internalisation as measured by diffusion-enhanced resonance energy transfer (DERET) [27]. D3-exendin-4 and [D3,G40,K41.C16 diacid]exendin-4 induced rapid internalisation, whereas none was detectable with either type of F1 ligand (Figure 1E, Supplementary Figure 1F, Table 1). These results were corroborated by confocal microscopy, which showed that surface-labelled SNAP-GLP-1R was predominantly relocated to punctate endosomal organelles after D3-exendin-4 and [D3,G40,K41.C16 diacid]exendin-4 treatment, but remained mainly at the plasma membrane with F1-exendin-4 and [F1,G40,K41.C16 diacid]exendin-4 (Figure 1F).

This initial in vitro characterisation demonstrated that the C16 diacid C-terminal conjugation was well tolerated by D3-exendin-4. Some
differences were however observed with the pharmacology of F1,G40,K41.C16 diacid exendin-4, which showed increased binding affinity but decreased signalling efficacy compared to F1-exendin-4, thereby magnifying signalling differences between the two oppositely biased ligands.

3.2. Acylated biased GLP-1RAs show prolonged pharmacokinetics

Acylation prolongs peptide pharmacokinetics by promoting reversible binding to plasma proteins that are too large to undergo glomerular filtration, such as albumin. To determine the extent of F1,G40,K41.C16 diacid exendin-4, D3,G40,K41.C16 diacid exendin-4, and the similarly designed G60,K41.C16 diacid exendin-4 (Supplementary Figure 2A) binding to plasma proteins, we used the EScale equilibrium shift assay [21]. The results indicated that each acylated ligand exhibited a high and similar degree of binding to mouse and human plasma proteins (Table 2, Supplementary Tables 1 and 2). In keeping with this, the presence of serum during the incubation did not differentially affect the signalling potency for each C16 ligand in GLP-1R cAMP assays compared to its non-acylated comparator (Supplementary Figure 2B), potency was in fact higher when serum was present for both acylated and non-acylated ligands, presumably due to reduced adsorption of peptide onto the microplate plastic surface. In this system, an approximately 100-fold potency difference between F1,G40,K41.C16 diacid exendin-4 and D3,G40,K41.C16 diacid exendin-4 was observed, along with reduced efficacy for the former (Table 1). The pharmacology of G60,K41.C16 diacid exendin-4 was evaluated in CHO—K1-βarr2-EA-GLP-1R cells, revealing preserved cAMP signalling potency with a clear reduction in β-arrestin-2 recruitment efficacy compared to exendin-4, conforming to the patterns observed with the F1 and D3 ligand pairs (Supplementary Figure 2C).

In keeping with the anticipated pharmacokinetic effect resulting from binding to plasma proteins, after a single injection in mice, G60,K41.C16 diacid exendin-4 remained detectable in the circulation for at least 72 h, in contrast to non-acylated exendin-4 (Figure 2A).
Table 2 — EScalate results demonstrating binding of each ligand to human and mouse peptide proteins. Data are expressed as mean ± SEM of the percentage of peptide unbound to plasma proteins determined in duplicate.

| Compound | Human plasma | Mouse plasma |
|----------|--------------|--------------|
| $[F1,G40,K41,C16]$exendin-4 | 2.3% ± 1.0% | 2.6% ± 0.1% |
| $[R3,G40,K41,C16]$exendin-4 | 2.1% ± 0.1% | 2.4% ± 0.3% |
| $[D3,G40,K41,C16]$exendin-4 | 2.2% ± 0.1% | 2.1% ± 0.3% |

considered the possibility of whether GLP-1R-mediated clearance may play a role in pharmacokinetics once glomerular filtration is no longer a primary route of elimination in a form of target-mediated drug disposal (TMDD) [28,29], but the absence of large differences in circulating concentrations of all three acylated ligands 24 and 72 h post-dosing argues against this possibility (Figure 2B).

Therefore, conjugation of a C16 diacid to the C-terminus of exendin-F1 and exendin-D3 results in a pair of pharmacokinetically advantageous and oppositely biased GLP-1RAs, allowing convenient assessment of the impact of signal bias and trafficking over multiple days.

3.3. Metabolic effects of biased GLP-1RAs are preserved after acylation

The primary therapeutic actions of GLP-1RAs are to improve glucose regulation and reduce appetite. We trialled a series of doses of $[F1,G40,K41,C16]$exendin-4 and $[D3,G40,K41,C16]$exendin-4 in lean C57Bl/6 mice to assess their in vivo performance over 72 h. Both ligands exhibited effective glucoregulatory properties (Supplementary Figure 3A), although $[F1,G40,K41,C16]$exendin-4 was less effective at 10 nmol/kg, which could reflect its reduced signalling potency. However, when reassessed at 72 h, $[D3,G40,K41,C16]$exendin-4 no longer exhibited any detectable anti-hyperglycaemic efficacy, whereas both of the higher $[F1,G40,K41,C16]$exendin-4 doses remained effective. The acute anorectic effect of $[D3,G40,K41,C16]$exendin-4 was somewhat greater than that of $[F1,G40,K41,C16]$exendin-4, particularly at the 10 nmol/kg dose (Supplementary Figure 3B), although, interestingly, by 72 h, the net calorie intake deficit with $[F1,G40,K41,C16]$exendin-4 at the highest dose was greater than that of $[D3,G40,K41,C16]$exendin-4. A dose response analysis of these data is displayed in Supplementary Figure 3C.

We also tested both compounds at an intermediate dose in obese mice fed a high-fat diet for 3 months. Consistent patterns were observed, with equal glucose lowering seen 2 h after dosing but a glycaemic advantage for $[F1,G40,K41,C16]$exendin-4 clearly demonstrated at 72 h (Figure 3A). The anorectic differences were more subtle than in lean mice, with non-significant trends observed 1 and 72 h after dosing (Figure 3B). A non-significant trend was also seen for body weight loss, with $[F1,G40,K41,C16]$exendin-4-treated mice losing slightly more weight at 72 h than those treated with $[D3,G40,K41,C16]$exendin-4 (Figure 3C).

The apparent greater efficacy with $[F1,G40,K41,C16]$exendin-4 at 72 h suggests that the impact of its biased pharmacology is preserved in vivo despite its considerably lower net signalling potency. As previously observed, these effects primarily concerned its glucoregulatory properties.

3.4. Sustained administration of acylated biased GLP-1RAs

We conducted a repeated administration study in high-fat diet-induced obese mice to compare the therapeutic effects of $[F1,G40,K41,C16]$exendin-4 and $[D3,G40,K41,C16]$exendin-4 with equal glucose lowering seen 2 h after dosing but a glycaemic advantage for $[F1,G40,K41,C16]$exendin-4 clearly demonstrated at 72 h (Figure 3A). The anorectic differences were more subtle than in lean mice, with non-significant trends observed 1 and 72 h after dosing (Figure 3B). A non-significant trend was also seen for body weight loss, with $[F1,G40,K41,C16]$exendin-4-treated mice losing slightly more weight at 72 h than those treated with $[D3,G40,K41,C16]$exendin-4 (Figure 3C).

The apparent greater efficacy with $[F1,G40,K41,C16]$exendin-4 at 72 h suggests that the impact of its biased pharmacology is preserved in vivo despite its considerably lower net signalling potency. As previously observed, these effects primarily concerned its glucoregulatory properties.
diacid\]exendin-4 and [D3,G40,K41.C16 diacid\]exendin-4 in a chronic setting. Mice were injected every 72 h over 15 d; the dose was doubled after the first 3 injections to counteract adaptive mechanisms typically seen in rodents treated with GLP-1RAs, which limit weight loss [30–32]. Over the course of the study, the trends observed in the single dose administration studies became more apparent, with a progressively greater anorectic effect observed with [F1,G40,K41.C16 diacid\]exendin-4, along with a corresponding divergence in body weight (Figure 4A,B). Glucose tolerance assessed 72 h after the final dose confirmed the expected advantage of [F1,G40,K41.C16 diacid\]exendin-4 over [D3,G40,K41.C16 diacid\]exendin-4 (Figure 4C). In a separately conducted study in which the glycaemic effects of each ligand were recapitulated (Supplementary Figure 4A), a non-significant trend toward increased beta and alpha cell mass was observed in the [F1,G40,K41.C16 diacid\]exendin-4-treated mice, with no change in the ratio of alpha to beta cells (Figure 4D).

Figure 2: Pharmacokinetic properties of acylated biased GLP-1RAs. (A) Plasma concentration of exendin-4 or [G40,K41.C16 diacid\]exendin-4 (both referred to as Exendin on the y-axis) in male C57Bl/6 mice after a single intraperitoneal injection of 100 nmol/kg agonist, n = 8 per treatment, two-way repeat measures ANOVA of log-transformed data with Sidak’s test. (B) Plasma concentration of [G40,K41.C16 diacid\]exendin-4 (n = 10), [F1,G40,K41.C16 diacid\]exendin-4 (n = 12), and [D3,G40,K41.C16 diacid\]exendin-4 (n = 11) in male C57Bl/6 mice after a single intraperitoneal injection of 100 nmol/kg agonist, two-way repeat measures ANOVA on log-transformed data with Sidak’s test. In this experiment, mice (n = 8) injected with vehicle recorded a nominal exendin plasma concentration of 5.8 pg/ml at 72 h, reflecting non-specific signalling at the lower limit of the assay. *p < 0.05 by statistical test indicated in the text. Error bars indicate SEM.

Figure 3: Sub-chronic effects of acylated biased GLP-1RAs in diet-induced obese mice. (A) Intra-peritoneal glucose tolerance tests (IPGTT, 2 g/kg glucose) conducted 2 or 72 h after IP administration of indicated -C16 agonist (10 nmol/kg) or vehicle (saline) in male diet-induced obese (DIO) C57Bl/6 mice, n = 10/group, time points and AUCs both compared by two-way repeat measures ANOVA with Tukey’s test, with comparisons between [F1,G40,K41.C16 diacid\]exendin-4 and [D3,G40,K41.C16 diacid\]exendin-4 are shown. (B) Cumulative food intake in male DIO C57Bl/6 mice after a single intraperitoneal injection of 100 nmol/kg agonist, n = 10/group, effect of each agonist to reduce food intake relative to vehicle at 1 and 72 h is shown separately. (C) Body weight change in the study shown in (B), two-way repeat measures ANOVA with Tukey’s test, comparison between [F1,G40,K41.C16 diacid\]exendin-4 and [D3,G40,K41.C16 diacid\]exendin-4 at 72 h is shown on the graph. *p < 0.05 by statistical test indicated in the text. Error bars indicate SEM.
Thus, the metabolic benefits of the biased GLP-1RA [F\(^1\),G\(^{40}\),K\(^{41}\),C\(^{16}\) diacid]exendin-4 were preserved on repeated administration and became progressively more apparent over time.

4. DISCUSSION

In the present study, we developed and tested two oppositely biased GLP-1RAs bearing C-terminal C\(^{16}\) diacid chains, which confer extended pharmacokinetic profiles. The major observation from our data is that, despite at least a large reduction in cAMP signalling potency (10- to 1000-fold depending on the cell system used), [F\(^1\),G\(^{40}\),K\(^{41}\),C\(^{16}\) diacid]exendin-4 was markedly more efficacious in vivo than oppositely biased [D\(^3\),G\(^{40}\),K\(^{41}\),C\(^{16}\) diacid]exendin-4. This finding builds on earlier reports highlighting the advantageous glucoregulatory properties of lower affinity biased GLP-1RAs that favour CAMP signalling over \(\beta\)-arrestin recruitment [11,12], but with a substantially greater disconnect between acute in vitro potency and anti-hyperglycaemic properties than for earlier compounds.

Some interesting in vitro observations arise from this work, particularly regarding comparisons of acylated vs non-acylated ligands. First, we found that the binding affinity of [F\(^1\),G\(^{40}\),K\(^{41}\),C\(^{16}\) diacid]exendin-4 was approximately 3 times greater than that of non-acylated exendin-F\(^1\), yet its CAMP signalling potency was between 5 and 20 times (for CHO-K1 and MIN6B1 cells, respectively) lower. One possible explanation for this is disruption of normal ligand–receptor interactions by the acyl chain in a manner that permits ligand binding but orientates the ligand so that its N-terminus fails to optimally engage with the receptor core, leading to reduced levels of activation. Structural and
computational studies will be required to reveal if this is the case, but may be hampered by the lack of confidence about the position of the exendin-4 C-terminus when bound to GLP-1R [33]. An alternative possibility, tentatively supported by recent reports that active GLP-1Rs segregate into cholesterol-rich nanodomains within the plasma membrane [17,34], is that fatty acid preferentially directs the ligand to bind to subpopulations of GLP-1Rs residing in membrane regions with reduced enrichment of signalling effectors on the cytoplasmic side. Should this be the case, the fact that nanodomain clustering is more extensive with exendin-D3 than exendin-F1 [17] could support our observation of greater potency loss with [F1,G40,K41,C16 diacid]exendin-4 than [D3,G40,K41,C16 diacid]exendin-4.

The addition of a C16 diacid moiety, as expected from other ligands tested as part of the preclinical development of C18 diacid-containing semaglutide [35,36], provided a high degree of binding to both mouse and human plasma proteins. The slightly lower affinity of the investigated compounds (2.08%—2.33% in human plasma) compared to liraglutide containing a C16 fatty acid moiety (0.51% in human plasma [21]) may be attributable to the shorter linker between the peptide and albumin binding group. In combination with resistance of exendin peptides to degradation by a variety of enzymes including dipeptidyl peptidase-4 and neutral endopeptidases [37], the two primary elimination routes for GLP-1 peptides are avoided, providing a basis for substantially extended pharmacokinetics in mice, with even longer protraction expected to be obtained in humans. We note a discrepancy between the absolute plasma levels recorded at 72 h for [G40,K41,C16 diacid]exendin-4 in the separately conducted experiments presented in Figure 2A,B, which we suspect results from assay-to-assay variability. Our evaluation of the pharmacodynamic performance of biased GLP-1RAs found clear evidence of improved anti-hyperglycaemic efficacy for [F1,G40,K41,C16 diacid]exendin-4. This is despite substantially reduced acute signalling potency of this molecule, highlighting how standard in vitro approaches may fail to identify optimal agonist characteristics. Although coupling to Gq recruitment was markedly increased, [D3,G40,K41,C16 diacid]exendin-4 resulted in superior cumulative reductions in food intake and greater weight loss than [D3,G40,K41,C16 diacid]exendin-4. As [F1,G40,K41,C16 diacid]exendin-4 tended to exert a milder appetite suppressive effect in the acute setting, enhanced tolerability might result while still achieving better weight loss and anti-hyperglycaemic efficacy. In this study, we did not compare these ligands against class-leading GLP-1RAs such as semaglutide and dulaglutide, and therefore their true therapeutic potential remains undetermined. Nevertheless, our results clearly show that agonists displaying weak acute signalling efficacy and potency can be surprisingly effective for therapeutically important readouts. We also did not test for development of anti-drug antibodies, which are common with exendin-4-derived peptides, albeit seemingly of little therapeutic relevance [42]. A further limitation of our work is that we examined only a limited series of canonical pathways for which a role in GLP-1R signal transduction was already established. Unbiased techniques that simultaneously measure multiple pathways, for example, phosphoproteomic or kinomic analysis, have the potential to enhance our understanding of the unusual pharmacology of biased GLP-1RA ligands and may shed light on new ways to control GLP-1R behaviours.

ACKNOWLEDGMENTS

This study was funded by an MRC project grant to B.J., A.T., S.R.B., and G.A.R, and supported by the EFSD/Boehringer Ingelheim European Research Programme on Multi-System Challenges in Diabetes to B.J. and A.T. The section on endocrinology and investigative medicine was funded by grants from the MRC, BBSRC, NHR, an Integrative Mammalian Biology (IMB) Capacity Building Award, and an FP7-HEALTH-2009-241592 EuroCHIP grant, and was supported by the NIHR Biomedical Research Centre Funding Scheme. The views expressed are those of the author(s) and not necessarily those of the funder. B.J. was also supported for this study by the Academy of Medical Sciences, Society for Endocrinology, and an EPSRC capital award. G.A.R. was supported by Wellcome Trust Investigator (212625/2/18/2) awards, MRC Programme (MR/R022259/1), an Experimental Challenge Grant (DWA, MR/L02036/1), and Diabetes UK (BDA/11/0004210, BDA/15/0005275, and BDA 16/0005485) grants. This study received support from the EU/EPPA/Innovative Medicines Initiative 2 Joint Undertaking (RHAPSODY grant No. 115881) to G.A.R. We are grateful to Prof. Nevin Lambert (Medical College of Georgia) for providing minG-LgBiT plasmids, Dr. Pauline Chabosseau (Imperial College London) for providing an ImageJ macro for islet analysis, and Lorraine Lawrence (Imperial College London) for assistance with histological sectioning.

CONFLICT OF INTEREST

J.U. and K.S. are employees of 3B Pharmaceuticals GmbH, a company which developed and commercialised the EScale assay.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2020.100991.

REFERENCES

[1] Andersen, A., Lund, A., Knop, F.K., Vilsbøll, T., 2018 Jul. Glucagon-like peptide 1 in health and disease. Nature Reviews Endocrinology 14(7):390—403.
[2] Mann, J.F.E., Ørsted, D.D., Brown-Forseten, K., Marso, S.P., Poultet, N.R., Rasmussen, S., et al., 2017 Aug 31. Lisrulglutide and renal outcomes in type 2 diabetes. New England Journal of Medicine 377(8):839—848.
Simonsen, L., Holst, J.J., Deacon, C.F., 2006 Apr. Exendin-4, but not
Chen, X., Mietlicki-Baase, E.G., Barrett, T.M., McGrath, L.E., Koch-
www.molecularmetabolism.com 9
MOLECULAR METABOLISM 37 (2020) 100991
Hager, M.V., Johnson, L.M., Wootten, D., Sexton, P.M., Gellman, S.H., 2016
Koole, C., Wootten, D., Simms, J., Miller, L.J., Christopoulos, A., Sexton, P.M., et al., 2011 Mar 2. Intracellular signals mediating the food intake-suppressive
effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metabo-
lism 13(3):320–330.
Buenaventura, T., Kanda, N., Douzenis, P.C., Jones, B., Bloom, S.R., Chat-
boseau, P., et al., 2018 Oct. Glucagon-like peptide-1 receptor internalisation
controls spatiotemporal signalling mediated by biased agonists. Biochemical Pharmacology 156:406–419.
Sonoda, N., Imamura, T., Yoshizaki, T., Babendure, J.L., Lu, J.-C., Olefsky, J.M., 2008 May 6. Beta-Arrestin-1 mediates glucagon-like peptide-1
signaling to insulin secretion in cultured pancreatic beta cells. Proceedings of the National Academy of Sciences of the United States of America 105(18):
6614–6619.
Koole, C., Wootten, D., Simms, J., Miller, L.J., Christopoulos, A., Sexton, P.M., et al., 2015 Apr. Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allosterity. Journal of Pharmacology and Experimental Therapeutics 353(1):52–63.
Zhang, H., Sturchler, E., Zhu, J., Nieto, A., Cistrone, P.A., Xie, J., et al., 2015 Dec 1. Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects. Nature Communication 6(1):8918. Nature Publishing Group,
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B.M., Scott, R., et al., 2018 Apr 23. Targeting GLP-1 receptor trafficking to improve agonist
efficacy. Nature Communication 9(1):1602. Nature Publishing Group,
Hager, M.V., Johnson, L.M., Wootten, D., Sexton, P.M., Getlman, S.H., 2016
Nov 16. β-Arrestin-Biased agonists of the GLP-1 receptor from β-amino acid
residue incorporation into GLP-1 analogues. Journal of the American Chemical Society 139(45):14970–14979.
Chen, X., Mietlicki-Baase, E.G., Barrett, T.M., McGrath, L.E., Koch-
Laskowski, K., Ferrie, J.J., et al., 2017 Nov 22. Thioamide substitution
residue incorporation into GLP-1 analogues. Journal of the American Chemical Society 139(46):16688–16695.
Fremaux, J., Venin, C., Mauran, L., Zimmer, R., Keersen, F., Rognan, D., et al., 2019 Nov 14. Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking. Chemical Science 10(42):9872–9879.
Simonsen, L., Holst, J.J., Deacon, C.F., 2006 Apr. Exendin-4, but not
glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 49(4):706–712.
Buenaventura, T., Bilis, S., Laughlin, W.E., Burgoine, T., Lyu, Z., Oqua, A.I., et al., 2019 Aug. Agonist-induced membrane nanodomain clustering drives
GLP-1 receptor responses in pancreatic beta cells. PLoS Biology 17(8):e3000097.
Widmann, C., Dolci, W., Thorens, B., 1995 Aug 15. Agonist-induced internal-
ization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in islet cells. Biochemical Journal 310(Pt 1):203–214.
Wan, G., Okashah, N., Inoue, A., Nehmè, R., Carpenter, B., Tate, C.G., et al., 2018 May 11. Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells. Journal of Biological Chemistry 293(19):7466–7473.
Kroeze, W.K., Sassano, M.F., Huang, X.-P., Lansk, K., McCory, J.D., Gi-guère, P.M., et al., 2015 May. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nature Structural Molecular Biology 22(5):362–369. Nature Publishing Group,
Ungeiss, J., Gerické, S., Boris, H., 2019 Mar. Determination of the plasma protein binding of lilaglutide using the ESclassic equilibrium shift assay. Journal of Pharmacological Sciences 108(3):1309–1314.
Johnston, N.R., Mitchell, R.K., Haythorne, E., Pessoa, M.P., Semplici, F., Ferrer, J., et al., 2016 Sep 13. Beta cell hubs dictate pancreatic islet re-
sponses to glucose. Cell Metabolism 24(3):389–401.
Stahl, E.L., Zhou, L., Ehret, F.J., Bohn, L.M., 2015 May. A novel method for analyzing extremely biased agonism at G protein-coupled receptors. Molecular Pharmacology 87(5):866–877.
Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., Novick, S., 2012 Mar 21. A simple method for quantifying functional selectivity and agonist bias. ACS Chemical Neuroscience 3(3):193–203.
van der Westhuizen, E.T., Breton, B., Christopoulos, A., Bouvier, M., 2014 Mar. Quantification of ligand bias for clinically relevant β2-adrenergic receptor li-
gands: implications for drug taxonomy. Molecular Pharmacology 85(3):492–509.
Dixon, A.S., Schwinn, M.K., Hall, M.P., Zimmerman, K., Otto, P., Lubben, T.H., et al., 2016 Feb 19. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chemical Biology 11(2):400–408.
Levyo, A., Zwier, J.M., Jaracz-Ros, A., Kipfel, L., Cottet, M., Maurel, D., et al., 2015. A broad G protein-coupled receptor internalization assay that combines SNAP-tag labeling, diffusion-enhanced resonance energy transfer, and a highly emissive terbium cryptate. Frontiers in Endocrinology (Lausanne) 6:167.
Gibiansky, L., Gibiansky, E., 2009 Jul. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opinion on Drug Metabolism and Toxicology 5(7):803–812.
Gao, W., Jusko, W.J., 2012 May. Target-mediated pharmacokinetic and
pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metabolism & Disposition 40(5):990–997.
Mondragon, A., Davidsson, D., Kyräkoski, S., Bertling, A., Gomes-Faria, R., Cohen, P., et al., 2014. Divergent effects of lilaglutide, exendin-4, and sita-
gliflozin on Beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia. PLoS One 9(8):e104873.
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D.A., Sandoval, D.A., Seeley, R.J., 2014 Jun. Neuronal GLP1R1 mediates lilaglutide’s anorectic but not glucose-lowering effect. Journal of Clinical Investigation 124(6):2456–2463.
Telbel, K.S., Kristiansen, M.N., Hansen, H.H., Veidal, S.S., Røgbølt, K.T., Gilm, M.P., et al., 2018 Jan 14. Metabolic and hepatic effects of lilaglutide, olicolic acid and efltorfen in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World Journal of Gastroenter-
ology 24(2):179–194. Bailington Publishing Group Inc.
Li, Y.-L., Khoshouei, M., Glukhova, A., Furness, S.G.B., Zhao, P., Clydesdale, L., et al., 2018. Phase-plate cys-te-OEM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. Nature 546:118–123. Nature Publishing Group,
Brief Communication

[34] Ast, J., Arvaniti, A., Fine, N.H.F., Nasteska, D., Ashford, F.B., Stamatakis, Z., et al., 2019 Feb 26. LUXendins reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. bioRxiv. Cold Spring Harbor Laboratory 4: 557132.

[35] Lau, J., Bloch, P., Schäffer, L., Pettersson, L., Spetzler, J., Kofod, J., et al., 2015 Sep 24. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry 58(18):7370–7380.

[36] Knudsen, L.B., Lau, J., 2019. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology (Lausanne) 10:155.

[37] Hupe-Sodmann, K., McGregor, G.P., Bridenbaugh, R., Göke, R., Göke, B., Thole, H., et al., 1995 Aug 22. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regulatory Peptides 58(3):149–156.

[38] Zhu, L., Almaça, J., Dadi, P.K., Hong, H., Sakamoto, W., Rossi, M., et al., 2017 Feb 1. β-arrestin-2 is an essential regulator of pancreatic β-cell function under physiological and pathophysiological conditions. Nature Communications 8:14295.

[39] Thompson, A., Kanamarlapudi, V., 2015 Jan 1. Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the Gq pathway. Biochemical Pharmacology 93(1):72–84.

[40] Secher, A., Jelsing, J., Baquero, A.F., Hecksher-Sørensen, J., Cowley, M.A., Dalboge, L.S., et al., 2014 Oct. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation 124(10):4473–4488.

[41] Steen, A., Larsen, O., Thiele, S., Rosenkilde, M.M., 2014. Biased and g protein-independent signaling of chemokine receptors. Frontiers in Immunology 5:1277.

[42] DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S., Baron, A.D., 2005 May. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28(5):1092–1100.